LatestJournalism Under Pressure: Puerto Rican Reporters' Experience Covering Tragedy
Cannabis

Cannabis Analytics Firm Headset Settles $1M COVID-19 Relief Loan Fraud Claim

TG Branfalt
Cannabis Analytics Firm Headset Settles $1M COVID-19 Relief Loan Fraud Claim
Summary

Cannabis analytics firm Headset Inc. has agreed to pay $1,012,876 to settle allegations that it improperly received a federal Paycheck Protection Program (PPP) loan intended for small businesses during the COVID-19 pandemic. The company was deemed ineligible for the SBA relief funding in 2021. This settlement reflects ongoing enforcement actions against businesses that misused pandemic relief resources. The case highlights regulatory scrutiny within the cannabis industry during government financial assistance programs.

Originally published on

Ganjapreneur

By TG Branfalt

Read full article(opens in new tab)

Fetched: September 10, 2026 at 10:02 AM

Related News

More news you might be interested in

View all
Got Purps? Understanding Cannabis Effects Through Flavonoids
Cannabis
AnxietyDepression

Got Purps? Understanding Cannabis Effects Through Flavonoids

Flavonoids—the molecules responsible for cannabis flower's vibrant colors and distinctive flavors—are emerging as key compounds in understanding how cannabis produces its therapeutic effects. Beyond their aesthetic role, these polyphenolic compounds interact with cannabinoids like THC and CBD to modulate the plant's pharmacological profile and user experience. Researchers are increasingly focused on how flavonoids contribute to the entourage effect, where multiple plant compounds work synergistically to enhance medicinal benefits for conditions ranging from anxiety to chronic pain. This deeper understanding of flavonoids could revolutionize strain selection and cannabis medicine customization for patients seeking targeted symptom relief.

11 hours ago
Cannabis Now
Federal Hemp Ban Could Force 68.1% of U.S. Hemp Businesses to Close
Cannabis

Federal Hemp Ban Could Force 68.1% of U.S. Hemp Businesses to Close

A Whitney Economics report indicates that a federal ban on intoxicating hemp products would force approximately 68.1% of U.S. hemp-related businesses to close. The ban, originally scheduled for November, was delayed one month in August through an amendment to federal funding legislation. This regulatory action could significantly impact the availability and accessibility of hemp-derived products, including those with potential therapeutic applications. The analysis highlights the substantial economic consequences for the hemp industry and implications for consumers who rely on these products.

13 hours ago
Ganjapreneur
New Mexico Cannabis Tracking System Transition Causes Business Disruptions and Financial Losses
Cannabis

New Mexico Cannabis Tracking System Transition Causes Business Disruptions and Financial Losses

New Mexico's transition to the New Mexico Seed to Sale (NMS2S) tracking system launched September 1 has created operational challenges for cannabis retailers unable to sell products, resulting in significant financial losses. The system replacement, which transitioned from the legacy BioTrack platform that went offline September 7, has left businesses struggling with technical issues during the changeover. This disruption affects the medical cannabis supply chain, potentially impacting patients who depend on consistent access to cannabis for therapeutic purposes. Industry stakeholders report steep losses as the new system stabilizes. The transition highlights the importance of coordinated regulatory technology implementations to minimize patient access disruptions.

13 hours ago
Ganjapreneur
Germany's Strict GMP Interpretation Could Reshape Medical Cannabis Import Standards
Cannabis

Germany's Strict GMP Interpretation Could Reshape Medical Cannabis Import Standards

Germany's medical cannabis sector faces new regulatory scrutiny as Hesse's health authority issues strict GMP (Good Manufacturing Practice) compliance guidelines for processing facilities. This interpretation focuses on pharmaceutical standards for imported cannabis materials, potentially requiring international supply chains to reorganize operations. The shift reflects Germany's maturation from a high-volume import phase toward stricter quality control measures. These changes could establish precedent for European medical cannabis regulations and affect sourcing strategies for licensed producers serving patients with various therapeutic needs.

19 hours ago
Revista Cáñamo